RecruitingNot ApplicableNCT05794386

SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation

SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation (SCARLET-AF Study)


Sponsor

Seoul National University Hospital

Enrollment

204 participants

Start Date

Feb 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This is a multicenter, randomized controlled trial to compare the recurrence of 1-year atrial arrhythmia after catheter ablation of atrial fibrillation (AF) between pulmonary vein isolation (PVI) and PVI with additional left atrial (LA) substrate modification based on the left atrial low-voltage area (LA LVA) in patients with persistent AF who had a moderate burden of LVA in LA (1cm2 to \<30%).


Eligibility

Min Age: 19 Years

Inclusion Criteria4

  • Ages eligible for the study: 19 years or older
  • Patients with symptomatic persistent AF who undergo AF catheter ablation due to continued AF even after anti-arrhythmic agents or
  • Patients with a burden of LA LVA (scar zone) of 1cm2 or more and less than 30% in 3D voltage mapping before the index catheter ablation are included in the randomized assignment group when performing catheter ablation in satisfaction with 1)
  • \) Patients with an LVA of \<1cm2 or ≥30% are recruited as a registry.

Exclusion Criteria16

  • Patients with LA anteroposterior diameter of more than 55 mm
  • Patients with prior AF-related catheter ablation or surgery
  • Patients whose exact LVA burden cannot be calculated because high-quality 3D voltage mapping cannot be obtained during the procedure.
  • Inability or unwillingness to receive anticoagulation (heparin or oral anticoagulation)
  • Known severe left ventricular systolic dysfunction (ejection fraction \<35%)
  • Patients with severe structural heart disease (severe mitral regurgitation, hypertrophy cardiomyopathy, other severe valvular heart diseases)
  • Patients with intracardiac thrombus
  • Patients with prior cardiac surgery
  • Patients who had a myocardial infarction or underwent percutaneous coronary intervention within three months
  • Patients who had a stroke or transient ischemic attack within 6 months
  • Patients who had a planned operation or procedure for the cardiovascular system
  • Patients with intractable hypertension or uncontrolled thyroid disease
  • Patients who need dialysis due to end-stage renal disease or who are scheduled for dialysis
  • Patients who are currently pregnant or are likely to be pregnant within the study period
  • Patients who are taking immunosuppressive drugs or had undergone chemotherapy for cancer, autoimmune disease, transplant, etc
  • Patients whose life expectancy is less than 1 year

Interventions

PROCEDURELVA-guided LA substrate modification

The LVA-guided additional LA ablation is included linear ablation or LVA zone border modification/isolation/ homogenization. The additional ablation strategies are finally selected at the physicians' discretion, considering LVA location and distribution.


Locations(1)

Seoul National University Hospital

Seoul, Jongno-gu, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05794386


Related Trials